Metformin combats obesity by targeting FTO in an m6A-YTHDF2-dependent manner

J Drug Target. 2022 Nov;30(9):983-991. doi: 10.1080/1061186X.2022.2071906. Epub 2022 May 9.

Abstract

Obesity has become a health threat and hard enough to deal with. Evidences show that metformin could inhibit adipogenesis and combat obesity, while its mechanisms remain to be elucidated more comprehensively. In this study, we found that administration of metformin could combat obesity of mice induced by high-fat diet (HFD), indicated by strikingly decreased body weight and weight of inguinal white adipose tissue (iWAT) and epidydimal white adipose tissue (eWAT) compared with the control group. Mechanically, we revealed that metformin could inhibit protein expression of FTO, leading to increased m6A methylation levels of cyclin D1 (Ccnd1) and cyclin dependent kinase 2 (Cdk2), two crucial regulators in cell cycle. Ccnd1 and Cdk2 with increased m6A levels were recognised by YTH m6A RNA binding protein 2 (YTHDF2), causing an YTHDF2-dependent decay and decreased protein expressions. In consequence, mitotic clonal expansion (MCE) process was blocked and adipogenesis was inhibited.

Keywords: FTO; MCE; Metformin; adipogenesis; obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / metabolism
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO / metabolism
  • Animals
  • Cyclin D1* / genetics
  • Cyclin D1* / metabolism
  • Cyclin-Dependent Kinase 2 / metabolism
  • Metformin* / pharmacology
  • Mice
  • Obesity / drug therapy
  • Obesity / genetics
  • Obesity / metabolism
  • RNA-Binding Proteins / metabolism
  • Transcription Factors / metabolism

Substances

  • RNA-Binding Proteins
  • Transcription Factors
  • Cyclin D1
  • Metformin
  • FTO protein, mouse
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO
  • Cyclin-Dependent Kinase 2